

MICRUS ENDOVASCULAR CORP

Form 8-K

July 10, 2006

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 5, 2006

Micrus Endovascular Corporation
(Exact name of registrant as specified in its charter)
000-51323
(Commission File Number)

Delaware
(State or Other Jurisdiction of
Incorporation)

23-2853441
(I.R.S. Employer Identification No.)

821 Fox Lane
San Jose, California 95131
(Address of principal executive offices, including zip code)
(408) 433-1400
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On July 5, 2006, Tom Holdych announced his intention to resign from his position with Micrus Endovascular Corporation (Micrus), effective July 14, 2006, in order to accept a position as Chief Executive Officer with an early stage diagnostic product company. Mr. Holdych has served as Senior Vice President and Chief Compliance Officer for Micrus.

-1-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MICRUS ENDOVASCULAR
CORPORATION
(Registrant)

Date: July 7, 2006

By: /s/ Robert A. Stern
Robert A. Stern
Executive Vice President, Chief
Financial
Officer, and Secretary

-2-